KRAS and colorectal carcinoma: CRC cell lines with BRAF V600E but not those with KRAS G12C, G12D, G12V, or G13D mutation responded to siRNA mediated BRAF inhibition by reduced proliferation and increased apoptosis [9], indicating that there are other branches of KRAS signaling that can support cell survival and proliferation.